Engineered Heparins: Novel β-Secretase Inhibitors as Potential Alzheimer’s Disease Therapeutics

Publisher： Karger

E-ISSN： 1660-2862|5|3-4|197-199

ISSN： 1660-2854

Source： Neurodegenerative Diseases, Vol.5, Iss.3-4, 2008-03, pp. : 197-199

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of γ-Secretase Inhibition on the Amyloid β Isoform Pattern in a Mouse Model of Alzheimer’s Disease

By  

Neurodegenerative Diseases, Vol. 6, Iss. 5-6, 2009-12 ,pp. : 258-262

Karger

Access to resources Recommend Favorite

The role of caspases in Alzheimer’s disease; potential novel therapeutic opportunities

By Rohn Troy  

Apoptosis, Vol. 15, Iss. 11, 2010-11 ,pp. : 1403-1409

Springer Publishing Company

Access to resources Recommend Favorite

Influence of Pharmacogenetic Factors on Alzheimer’s Disease Therapeutics

By  

Neurodegenerative Diseases, Vol. 5, Iss. 3-4, 2008-03 ,pp. : 176-178

Karger

Access to resources Recommend Favorite

α-Secretase Activation – An Approach to Alzheimer’s Disease Therapy

By  

Neurodegenerative Diseases, Vol. 3, Iss. 4-5, 2006-10 ,pp. : 255-261

Karger

Access to resources Recommend Favorite

Lithium, a Potential Protective Drug in Alzheimer’s Disease

By  

Neurodegenerative Diseases, Vol. 5, Iss. 3-4, 2008-03 ,pp. : 247-249

Karger

Access to resources Recommend Favorite